Concord Biotech Limited (CONCORDBIO) Earnings Call Transcripts

Concord Biotech Limited's Latest Earnings Call - Q4 FY2026

In Q4 and FY '26, Concord Biotech Limited reported significant revenue challenges, with a 24% decline in Q4 revenue and a 12% decline for the fiscal year, attributed to geopolitical headwinds and supply chain disruptions. The company generated INR 829 crores in total revenue for FY '26, with a profit after tax of INR 260 crores, reflecting a 30% decrease year-over-year. Management expressed optimism for FY '27, citing improved visibility and a potential growth rate exceeding historical levels of 18% to 20%.

Reported metrics

Guidance from management

Management expects FY '27 growth to exceed historical rates of 18%, with strong visibility in the first half. They anticipate that operational leverage will positively impact margins as new facilities ramp up production.

What management said

So we have a very good amount of visibility in the first half. And based on that, we have been pretty confident that the coming financial year, we should expect the growth which should be better off than our historical growth, which has been there. So there is a fair amount of visibility in the first half.

See, I mean, I would say gross margins to be kind of in a similar range because one sees that there has been some pressure on the supplies of the goods. And of course, I don't expect that to be there for the full year, and we are procuring a lot of raw materials as well. So there is some impact on some of the products, some of the raw materials. So I don't expect it to be significantly different, but my sense would...

What analysts pressed on

Analysts expressed concerns regarding the timing of revenue recovery and the impact of geopolitical issues on future sales. There were questions about the sustainability of margins and the potential for write-offs related to inventory.

Main topics on the call

• Revenue Decline — Concord Biotech experienced a revenue decline of 24% in Q4 and 12% for FY '26, primarily due to geopolitical headwinds and supply chain disruptions. Management noted, "the impacted supplies were deferred to subsequent pe...
• Operational Challenges — The company faced operational challenges, particularly in the U.S. and Middle East markets, which impacted sales. Management stated, "A major tender in the region remains in advance, which adversely impacted our revenues...
• Regulatory Approvals — Concord successfully completed multiple regulatory inspections, including U.S. FDA and WHO-GMP certifications, enhancing its global compliance standards. This positions the company for future growth, as noted by manageme...
• Future Growth Outlook — Management is optimistic about FY '27, expecting growth to be better than historical rates of 18%. They stated, "We have a very good amount of visibility in the first half," indicating confidence in recovery and growth.

Read the full Concord Biotech Limited transcript (Q4 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 10 Concord Biotech Limited earnings call transcripts on record, spanning September 7, 2023 to August 3, 2026. Based on this history, Concord Biotech Limited reports semi-annually. The most recent call on file is dated August 3, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

CONCORDBIO

Exchange

NSEI

Country

IN

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

10

First call

September 7, 2023

Most recent

August 3, 2026

Reporting cadence

semi-annually